Inducible BRAF suppression models for melanoma tumorigenesis

Related Experiment Video

Updated: Jul 6, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Klaus P Hoeflich1, Bijay Jaiswal, David P Davis

  • 1Genentech Inc., Department of Molecular Biology, South San Francisco, CA, USA.

Methods in Enzymology
|April 1, 2008
PubMed

Insights

BRAF mutations are common in melanoma and benign nevi. Despite early occurrence, BRAF is essential for melanoma growth and maintenance, requiring additional genetic changes for progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Somatic BRAF mutations, particularly V600E, are prevalent in 50-70% of melanomas.
  • BRAF V600E mutations constitutively activate ERK signaling, promoting melanoma cell proliferation and survival.
  • BRAF mutations also occur in benign nevi, suggesting they are an early event but not sufficient for melanoma development.

Purpose of the Study:

  • To investigate the role of BRAF in melanoma pathogenesis and maintenance.
  • To understand why BRAF mutations in benign nevi rarely lead to melanoma.

Main Methods:

  • Analysis of BRAF mutation prevalence in melanoma and nevi.
  • Utilizing inducible shRNA for targeted BRAF knockdown in melanoma cell lines.
  • Assessing tumor growth and maintenance in xenograft models following BRAF knockdown.

Main Results:

  • BRAF mutations are found in a high percentage of both melanomas and benign nevi.
  • Targeted BRAF knockdown in BRAF-mutated melanoma cell lines significantly impaired tumor growth and maintenance in vivo.
  • This indicates BRAF is crucial for the survival and proliferation of established melanoma.

Conclusions:

  • BRAF mutations are necessary but not sufficient for melanoma progression, requiring additional genetic alterations.
  • Targeting BRAF is a viable therapeutic strategy for established melanomas harboring these mutations.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...